AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs
AbbVie (NYSE: ABBV) announced a USD 380 million investment to build two new active pharmaceutical ingredient (API) manufacturing...
Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development
Dartsbio Pharmaceuticals announced an exclusive licensing agreement with Slate Medicines, Inc., a US‑based emerging biopharmaceutical...
Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced an exclusive license agreement with Abbott for the commercialization...
SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic
SinoMab BioScience Limited (HKG: 3681) announced that China’s National Medical Products Administration (NMPA) has approved the...
Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...
Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic
Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that China’s National Medical Products Administration (NMPA) has...
CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years
CanSino Biologics (HKG: 6185) announced that China’s National Medical Products Administration (NMPA) has approved a supplementary...
Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis
Insilico Medicine (HKG: 3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to...
YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration
YolTech Therapeutics, a China‑based mRNA therapy and gene therapy developer, announced a strategic partnership with...
J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline
Johnson & Johnson (J&J, NYSE: JNJ) announced a more than USD 1 billion investment to build a next‑generation...
Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership
Frontier Biotechnologies Inc. (SHA: 688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK), granting the UK...
J&J’s RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved an extension...
Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal – Expands Global Footprint for CTLA‑4 Asset
Harbour BioMed (HKG: 2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical‑stage...
CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that China’s National Medical Products Administration (NMPA) has granted...
Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has accepted...
Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its iza‑bren, a first‑in‑class EGFR×HER3 bispecific antibody‑drug...
FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies
The U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the...
Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel
Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ: ACLX) for USD 115.00...
Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry
Pfizer Inc. (NYSE: PFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd....